Roche Vabysmo prefilled syringe approved in EU for three retinal conditions that can cause blindness Ruchika Sharma15 Dec 2024 1:15 PM ISTBasel: Roche has announced that the European Medicines Agency has approved Vabysmo (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use...
Roche Vabysmo prefilled syringe bags USFDA nod for three causes of vision loss Ruchika Sharma6 July 2024 4:34 PM ISTVabysmo PFS delivers the same medicine as the currently available Vabysmo vials in an alternative, ready-to-use format.
Roche Vabysmo gets CHMP recommendation for third indication retinal vein occlusion Ruchika Sharma29 Jun 2024 10:00 AM ISTBasel: Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive...
Roche Pharma India forays into Ophthalmology space with launch of Vabysmo Ruchika Sharma6 March 2024 4:10 PM ISTAs the world's first bispecific antibody, Vabysmo is a single molecule designed to target and inhibit the effects of two targets, providing the...
Roche bags USFDA nod for Vabysmo to treat retinal vein occlusion Ruchika Sharma27 Oct 2023 11:32 AM IST"Vabysmo is a new treatment option for RVO that can help people preserve and improve their vision, with the added benefit of retinal drying," said...
Vabysmo maintained vision improvements with extended treatment intervals up to 4 months for people with retinal vein occlusion in phase III studies: Roche Ruchika Sharma10 Oct 2023 2:30 PM ISTBasel: Roche has announced positive topline long-term results from the global phase III BALATON and COMINO studies, evaluating extended treatment...
US FDA declines to approve Regeneron's higher dose Eylea Ruchika Sharma30 Jun 2023 11:00 AM ISTRegeneron was seeking approval for the drug to treat wet AMD, the leading cause of blindness among the elderly, and two eye diseases that are common...
Roche Canada, pan-Canadian Pharmaceutical Alliance complete negotiations for VABYSMO to treat Neovascular neovascular AMD, DME Ruchika Sharma30 May 2023 5:46 PM ISTVABYSMO is a humanized bispecific immunoglobulin G1(IgG1) antibody that acts through inhibition of both Ang-2 and vascular endothelial growth factor A...
USFDA accepts application for Roche Vabysmo for retinal vein occlusion treatment Ruchika Sharma9 May 2023 11:42 AM ISTRetinal vein occlusion is the second most common cause of vision loss due to retinal vascular diseases.
BALATON, COMINO phase III studies of Vabysmo for people with retinal vein occlusion meet primary endpoints: Roche Ruchika Sharma30 Oct 2022 4:30 PM ISTBasel: Roche has announced positive topline results from two global phase III studies, BALATON and COMINO, evaluating the first and only bispecific...
Roche gets European Commission approval for Vision loss drug Vabysmo Ruchika Sharma20 Sept 2022 12:45 PM ISTBasel: Roche has announced that the European Commission (EC) has approved Vabysmo (faricimab) for the treatment of neovascular or 'wet' age-related...
Roche gets USFDA nod for injectable eye medicine Vabysmo Ruchika Sharma1 Feb 2022 1:37 PM ISTBasel: Roche has recently announced that the U.S. Food and Drug Administration (USFDA) has approved Vabysmo (faricimab-svoa) for the treatment of...
